SUPN Supernus Pharmaceuticals
- 30.480
- +0.400+1.33%
Supernus Pharmaceuticals News
Busy Philipps Shines Spotlight on ADHD in Women and Shares Her Qelbree Story
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with QelbreeThe percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready
By Ben Glickman Shares of Supernus Pharmaceuticals dropped Monday after regulators determined the company's new drug application was not ready for approval. The stock was down 6.9% to $31.23 in afte
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
Supernus Pharmaceuticals (SUPN) said Monday the Federal Drug Administration had issued a Complete Response Letter in response to its new drug application for SPN-830, a setback for the investigational
Supernus Stock Slides as FDA Rejects Parkinson's Disease Infusion Device
Express News | Supernus Pharmaceuticals Shares Are Trading Lower After the Company Announced the FDA Has Issued a Complete Response Letter in Response to the Company's New Drug Application for SPN-830
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV)
Supernus Provides Regulatory Update For SPN-830, FDA Has Issued A CRL In Response To The Co's NDA For Spn-830 Indicating That The Review Cycle For The Application Is Complete, But That The Application Is Not Ready For Approval In Its Present Form.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$511.68K in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 14,491 shares of Common Stocks on Mar 21, 2024 at an average price of $35.31 for a total value of $511.68K.Source: Announcement What
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer, on March 21, 2024, sold 14,491 shares in Supernus Pharmaceuticals (SUPN) for $511,677. Following the Fo
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$14,124 in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 400 shares of Common Stocks on Mar 20, 2024 at an average price of $35.31 for a total value of $14,124.Source: Announcement What is
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$436.57K in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 12,364 shares of Common Stocks on Mar 19, 2024 at an average price of $35.31 for a total value of $436.57K.Source: Announcement What
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer, on March 19, 2024, sold 12,364 shares in Supernus Pharmaceuticals (SUPN) for $436,573. Following the Fo
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$2.1 Million in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 62,366 shares of Common Stocks on Mar 13, 2024 at an average price of $33.74 for a total value of $2.1 million.Source: Announcement
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$128.13K in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 3,884 shares of Common Stocks on Mar 12, 2024 at an average price of $32.99 for a total value of $128.13K.Source: Announcement What
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
11 Best Small Cap Pharma Stocks to Invest In
Supernus Pharmaceuticals(SUPN.US) Officer Sells US$151.05K in Common Stocks
$Supernus Pharmaceuticals(SUPN.US)$ Officer Bhatt Padmanabh P. sold 5,000 shares of Common Stocks on Feb 26, 2024 at an average price of $30.21 for a total value of $151.05K.Source: Announcement What
Analysis
Price Target
No Data
